Hi Tech Medicines In Ireland
The Hi Tech medicines scheme was first introduced in Ireland by the HSE in 1996. The scheme involves the supply & dispensing of Hi Tech medicines through Community pharmacies.
Accord Healthcare recognises that the increased demand for prescription drugs and new treatments means that there is an ongoing need to deliver meaningful value for money to the state. With this in mind, we have developed a wide ranging portfolio of generic Hi Tech medicines, covering several therapeutic areas, outlined below.
As the generic Hi Tech product is priced 60% below the branded product, when you dispense items from the Accord Hi Tech portfolio, you are not only helping to provide a quality treatment for patients, but you are also helping the state to make considerable savings, which allows access to new medicines allowing patients access to treatments they require.
Voriconazole
- 50 mg x 28 Film Coated Tablets
- 200 mg x 28 Film Coated Tablets
Capecitabine
- 150 mg x 60 Film Coated Tablets
- 300 mg x 60 Film Coated Tablets
- 500 mg x 120 Film Coated Tablets
Temozolomide
- 5 mg x 5 Hard Capsules
- 20 mg x 5 Hard Capsules
- 100 mg x 5 Hard Capsules
- 140 mg x 5 Hard Capsules
- 180 mg x 5 Hard Capsules
- 250 mg x 5 Hard Capsules
Mycophenolate Mofetil
- 250 mg x 100 Capsules
- 500 mg x 50 Film Coated Tablets
Tenofovir disoproxil
- 245 mg x 30 Film Coated Tablets
Hi Tech Medicines In Ireland
The Hi Tech medicines scheme was first introduced in Ireland by the HSE in 1996. The scheme involves the supply & dispensing of Hi Tech medicines through Community pharmacies.
These products are usually prescribed on initiated in hospital and include items such as anti-rejection drugs for transplant patients or medicines used in conjunction with chemotherapy or hormonal therapy.
The principle difference between the GMS scheme and the Hi Tech scheme, is that rather than the pharmacy purchasing the product and getting reimbursed by the HSE, in recognition of the high cost of the Hi Tech product, it is distributed to the retail pharmacy and invoiced at zero cost, while simultaneously the distributor invoices the HSE directly. The pharmacist receives a patient care fee of €62.03 for each patient on the Hi Tech scheme.
The cost of Hi Tech drugs to the state has increased by 90%* since 2009, and with the spiralling cost of new treatments it is set to continue to rise year on year.
Accord Healthcare recognises that the increased demand for prescription drugs and new treatments means that there is an ongoing need to deliver meaningful value for money to the state. With this in mind, we have developed a wide ranging portfolio
of generic Hi Tech medicines, covering several therapeutic areas, such as Oncology, Neutropenia and Immunosuppressant’s to mention but a few. The combined total market value of the Accord Hi Tech portfolio is €31 million**.
As the generic Hi Tech product is priced 60% below the branded product, when you dispense items from the Accord Hi Tech portfolio, you are not only helping to provide a quality treatment for patients, but you are also helping the state to make considerable savings, which allow access to new medicines allowing patients access to treatments they require.
For further information please contact your Accord representative, or call the Accord office in Cork on 021 461 9040
* The Irish Times, 19th June 2017, article - Patients may face difficulty accessing lifesaving medicines.
** IMS Data April 2017.
